OX40-Enhanced Tumor Rejection and Effector T Cell Differentiation Decreases with Age
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OX40 agonists have potent immunotherapeutic effects against a variety of murine tumors, yet it is unclear the role that age-related immune senescence plays on their efficacy. We found that middle-aged and elderly tumor-bearing mice (12 and 20 mo old, respectively) treated with anti-OX40 were less responsive compared with young mice 6 mo or less of age. Decreased tumor-free survival was observed in both male and female mice, and was not due to changes in the surface expression of OX40 on T cells in older animals. Enumeration of cytokine-producing effector T cells in tumor-bearing mice revealed a significant decline in these cells in the older mice treated with anti-OX40 compared with their younger counterparts. The decrease of this critical T cell population in middle-aged mice was not a result of inherent T cell deficiencies, but was revealed to be T cell extrinsic. Finally, combining IL-12, an innate cytokine, with anti-OX40 boosted levels of differentiated effector T cells in the older anti-OX40-treated mice and partially restored the defective antitumor responses in the middle-aged mice. Our data show that the anti-OX40-enhancement of tumor immunity and effector T cell numbers is decreased in middle-aged mice and was partially reversed by coadministration of the proinflammatory cytokine IL-12.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1×
“In cancer patients, the generation and accumulation of effector T cells are critical for effective antitumor responses, as the presence of these cells within tumors in large numbers represents a positive clinical prognosis (26, 27).”
BackgroundInflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo
Haynes, L., Eaton, S. M., Burns, E. M., Rincon, M., & Swain, S. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5194 · Cited by 162
Cited by
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Fu, Y., Lin, Q., Zhang, Z., & Zhang, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.010 · Cited by 260
Effects of aging on T cell function
Haynes, L., & Maue, A. C. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.05.009 · Cited by 244
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Linch, S. N., McNamara, M. J., & Redmond, W. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00034 · Cited by 238
The effects of age and systemic metabolism on anti-tumor T cell responses
Drijvers, J. M., Sharpe, A. H., & Haigis, M. C. (2020) · eLife · doi:10.7554/elife.62420 · Cited by 69
“…(e.g. TLRs or OX40) and cancer vaccination strategies (using DNA, tumor cells or dendritic cells), are less effective in aged animals (Castro et al., 2009; Dominguez and Lustgarten, 2008; Grolleau- Julius et al., 2008; Provinciali et al., 2003; Provinciali et al., 2000; Ruby and Weinberg, 2009).”
BackgroundConsiderations for successful cancer immunotherapy in aged hosts
Hurez, V, Padrón, Á. S., Svatek, R. S., & Curiel, T. J. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12875 · Cited by 65
Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model
Padrón, Á., Hurez, V., Gupta, H. B., Clark, C. A., Pandeswara, S. L., Yuan, B., Svatek, R. S., Turk, M. J., Drerup, J. M., Li, R., et al. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2017.12.025 · Cited by 44
Metadata
- Authors
- Ruby, C. E., & Weinberg, A. D.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-02-01
- Volume
- 182
- Issue
- 3
- Pages
- 1481-1489
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1909396855
- Cited by
- 42
- References
- 2
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.